207_Combined course Presentations

Conclusions – PCNSL

 MTX + Rituximab containing regimen is significantly more active and effective than the other

combinations leading to high rates of CR ( ≃ 50%) and ORR (85-90%), and should be considered the

new standard induction for PCNSL

 A Consolidative therapy is strongly recommended after induction chemotherapy for PCNSL

 WBRT and ASCT are both active and effective , as consolidation therapies after high-dose-

methotrexate-based chemoimmunotherapy with a 95% CR rate, and 75-80% progression-free

survivors at 2 years

 The best consolidative approach should be selected “case by case” and tailored to the patients

within a multidisciplinary tumor board, taking into account the toxicity profile of each strategy.